Paradigm Shift In Parkinson’s Disease Diagnosis

Opinion
Video

The neurology experts discuss the importance of early and accurate diagnosis of Parkinson’s disease, the role of alpha-synuclein in the diagnosis of synucleinopathies and approaches to implementing screening protocols in clinical practice.

0:00 Introduction

01:15 Progress and Challenges in the Diagnosis of Parkinson’s Disease

07:27 Prodromal Symptoms in Parkinson’s Disease

11:19 Validation and Reevaluation of Parkinson’s Disease Diagnosis

15:20 Biomarkers in Parkinson’s Disease

21:28 DaTscan in Parkison’s Disease

26:33 Syn-one Test and Synucleinopathies

28:58 Use of Syn-One Test in Clinical Practice

34:41 Upcoming Changes in Diagnosis of Parkinson’s Disease

39:46 Future of Parkinson’s Disease Diagnosis

41:39 Final remarks

CORRECTION: At 32:59, Dr Isaacson notes that “This test was developed up in Boston by Roy Freeman and Chris Gibbons and now it’s been licensed to CND Life Sciences.” More precisely, the Syn-One Test is supported by technology licensed from Beth Israel Deaconess Medical Center in Boston, a Harvard Medical School Affiliate.

CORRECTION: At 33:02, Dr Isaacson states the Syn-One Test is covered by Medicare and that prior authorization is not required. More specifically stated, CND Life Sciences is a Medicare participating provider and has received reimbursement for the Syn-One Test consistently (although no formal coverage policy is currently in place for skin-based alpha-synuclein testing). CND helps clinicians and patients determine expected benefits coverage prior to scheduling the skin biopsy.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.